Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family ...

Background: There is sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), where lesions beyond pulmonary vein isolation (PVI) ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Atrial fibrillation is the most common chronic arrhythmia. It is characterized by erratic atrial electrical activity with atrial rates of 400 to 600 beats per minute. The P wave is absent on the ...

One-year clinical trial data for the next-generation, investigational, Sphere-360TM single-shot PFA catheter show impressive safety, perf ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Boston Scientific’s FARAPULSE system is showing some serious promise in zapping away persistent atrial fibrillation, ...

Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...